Sørensen Sofie Sølvsten, Nygaard Ann-Britt, Carlsen Anting Liu, Heegaard Niels H H, Bak Mads, Christensen Thomas
Department of Neurology, Nordsjællands Hospital, University of Copenhagen, Dyrehavevej 29, 3400 Hillerød, Denmark.
Department of Clinical Biochemistry, Nordsjællands Hospital, Hillerød, Denmark.
Biomark Res. 2017 Jul 11;5:24. doi: 10.1186/s40364-017-0104-9. eCollection 2017.
The purpose of this study was to investigate the potential of cerebrospinal fluid miRNAs as diagnostic biomarkers of acute ischemic stroke using three different profiling techniques in order to identify and bypass any influence from technical variation.
Cerebrospinal fluid (CSF) from patients with acute ischemic stroke ( = 21) and controls ( = 21) was collected by lumbar puncture. miRNA analysis was performed with three different methods: 1) Trizol RNA extraction followed by Illumina Next Generation Sequencing (NGS) on all small RNAs, 2) Exiqon RNA extraction protocol and miRNA qPCR assays, and 3) validation of 24 selected miRNAs with Norgen Biotek RNA extraction protocol and Applied Biosystems qPCR assays.
NGS detected 71 frequently expressed miRNAs in CSF of which brain-enriched miR-9-5p and miR-128-3p were significantly higher in CSF of stroke patients compared to controls. When dividing stroke patients into groups according to infarct size several brain-enriched miRNAs (miR-9-5p, miR-9-3p, miR-124-3p, and miR-128-3p) were elevated in patients with infarcts >2 cm3. This trend appeared in data from both NGS, qPCR (Exiqon), and qPCR (Applied Biosystems) but was only statistically significant in some of the measurement platforms.
Several brain-enriched miRNAs are elevated in the CSF three days after stroke onset, suggesting that these miRNAs reflect the brain damage caused by ischemia. The expression differences seem, however, limited to patients with larger ischemic brain injury, which argues against the use of CSF miRNAs as diagnostic biomarkers of stroke based on current methods.
本研究旨在使用三种不同的分析技术研究脑脊液微小RNA(miRNA)作为急性缺血性中风诊断生物标志物的潜力,以识别并绕过技术差异的任何影响。
通过腰椎穿刺收集急性缺血性中风患者(n = 21)和对照组(n = 21)的脑脊液(CSF)。使用三种不同方法进行miRNA分析:1)Trizol RNA提取,随后对所有小RNA进行Illumina下一代测序(NGS);2)Exiqon RNA提取方案和miRNA定量聚合酶链反应(qPCR)检测;3)使用Norgen Biotek RNA提取方案和Applied Biosystems qPCR检测对24种选定的miRNA进行验证。
NGS在脑脊液中检测到71种频繁表达的miRNA,其中与对照组相比,中风患者脑脊液中脑富集的miR-9-5p和miR-128-3p显著更高。当根据梗死面积将中风患者分组时,梗死面积>2 cm³的患者中几种脑富集的miRNA(miR-9-5p、miR-9-3p、miR-124-3p和miR-128-3p)升高。这种趋势在NGS、qPCR(Exiqon)和qPCR(Applied Biosystems)的数据中均有出现,但仅在某些测量平台上具有统计学意义。
中风发作三天后,脑脊液中几种脑富集的miRNA升高,表明这些miRNA反映了缺血引起的脑损伤。然而,表达差异似乎仅限于缺血性脑损伤较大的患者,这表明基于目前的方法,脑脊液miRNA不能作为中风的诊断生物标志物。